Bleakley Financial Group LLC bought a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 12,802 shares of the company’s stock, valued at approximately $1,349,000.
Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Protagonist Therapeutics by 27.2% during the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after purchasing an additional 1,156,461 shares during the last quarter. State Street Corp grew its stake in shares of Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after buying an additional 500,924 shares during the period. Wellington Management Group LLP increased its holdings in shares of Protagonist Therapeutics by 66.2% during the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after buying an additional 1,262,977 shares during the last quarter. UBS Group AG raised its position in shares of Protagonist Therapeutics by 46.1% in the 4th quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock worth $241,934,000 after buying an additional 874,013 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of Protagonist Therapeutics by 140.7% in the 4th quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock worth $231,355,000 after buying an additional 1,549,160 shares during the period. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
Protagonist Therapeutics Stock Performance
Shares of NASDAQ:PTGX opened at $140.91 on Friday. The business’s 50-day simple moving average is $113.50 and its 200 day simple moving average is $99.64. The company has a market cap of $9.06 billion, a P/E ratio of -77.85 and a beta of 1.79. Protagonist Therapeutics, Inc. has a one year low of $50.49 and a one year high of $141.10.
Insider Activity
In related news, CFO Asif Ali sold 1,750 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $105.47, for a total transaction of $184,572.50. Following the completion of the sale, the chief financial officer directly owned 59,003 shares of the company’s stock, valued at approximately $6,223,046.41. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bryan Giraudo sold 6,000 shares of Protagonist Therapeutics stock in a transaction on Friday, May 8th. The stock was sold at an average price of $100.00, for a total transaction of $600,000.00. Following the sale, the director directly owned 31,825 shares in the company, valued at $3,182,500. This trade represents a 15.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 162,880 shares of company stock valued at $16,539,792 in the last 90 days. Company insiders own 5.19% of the company’s stock.
Analyst Ratings Changes
PTGX has been the subject of a number of research reports. The Goldman Sachs Group reissued a “neutral” rating and set a $110.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Protagonist Therapeutics in a report on Friday, May 15th. Zacks Research raised Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Citizens Jmp increased their target price on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Barclays raised their price target on shares of Protagonist Therapeutics from $119.00 to $151.00 and gave the company an “overweight” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $123.00.
View Our Latest Stock Analysis on PTGX
Protagonist Therapeutics Profile
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.
Read More
- Five stocks we like better than Protagonist Therapeutics
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
